Sec. 753. Funding for rapid screening under Development of Medical Countermeasures Against Novel Entities program
160 words·~1 min read·
/bill/117/hr/4350/pcs/section-753·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
Notwithstanding the amounts set forth in the funding tables in division D, the amount authorized to be appropriated in section 4201 for Advanced Component Development & Prototypes, Research, Development, Test, and Evaluation, Defense-Wide, as specified in the corresponding funding table in section 4201, for the Chemical and Biological Defense Program- DEM/VAL, Line 82, is hereby increased by $4,500,000 for the Development of Medical Countermeasures Against Novel Entities program of the Defense Threat Reduction Agency, to allow for the rapid screening of all compounds approved by the Food and Drug Administration, and other human-safe compound libraries, to identify optimal drug candidates for repurposing as medical countermeasures for COVID–19 and other novel and emerging biological threats.
Notwithstanding the amounts set forth in the funding tables in division D, the amount authorized to be appropriated in section 4201 for Operations and Maintenance, Defense-Wide, as specified in the corresponding funding table in 4301, for Defense Media Activity, Line 370, is hereby reduced by $4,500,000.